Consensus Amgen Inc.

Stocks

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 22:55:15 28/08/2026 +04			5-day change	1st Jan Change
431.46 ^USD	-1.27%		-1.87%	+31.72%

08-27	UK Shares Fall as Global Tensions Mount; AstraZeneca Drops	MT
08-27	European Stocks Close Mostly Lower in Thursday Trading as Investors Await Fed Chair Speech	MT

Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

a6ed52784538a5f.DnLqwNOhQ2oHsMevogMXMtgEmWCp8Ch7LmQyVfIO0KA.bT-SlYTQNxND36jh-jNNdOx18BLOtU9ORB0EY99hgeJFCK2qm-YaBWXCig~6b3bb2f7d3a78aaa7df9e84f8aeaf002

Analysts' recommendations: Amgen Inc.

08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
08-18	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
08-17	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
08-13	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
08-13	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
08-10	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
08-07	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
08-06	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
08-05	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
08-05	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
08-05	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
08-05	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
08-05	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT
08-05	TD Cowen Adjusts Price Target on Amgen to $452 From $420, Maintains Buy Rating	MT
08-05	Goldman Sachs Adjusts Price Target on Amgen to $450 From $427, Maintains Buy Rating	MT
08-05	BMO Capital Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating	MT
08-05	Scotiabank Adjusts Price Target on Amgen to $450 From $385, Maintains Sector Outperform Rating	MT
08-05	Canaccord Genuity Adjusts Price Target on Amgen to $384 From $366, Maintains Hold Rating	MT
08-05	Baird Adjusts Price Target on Amgen to $230 From $215, Maintains Underperform Rating	MT
08-05	Oppenheimer Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating	MT
08-05	BofA Adjusts Price Target on Amgen to $317 From $312	MT
08-05	RBC Capital Adjusts Price Target on Amgen to $400 From $370, Maintains Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMGEN INC.					-11.1%
	ELI LILLY AND COMPANY					+11.81%
	JOHNSON & JOHNSON					+2.53%
	ABBVIE INC.					+7.14%
	ROCHE HOLDING AG					+1.73%
	NOVARTIS AG					-0.5%
	ASTRAZENECA PLC					+29.14%
	NOVO NORDISK A/S					+4.91%
	GILEAD SCIENCES, INC.					+5.74%
	PFIZER INC.					+2.09%
	Average					+5.35%
	Weighted average by Cap.					+6.50%